News About: Pharm. Industry
Whanin signs co-promotion agreement with Lundbeck Korea
Whanin Pharm says it has signed an agreement with Lundbeck Korea to co-promote and distribute nalmefene, an opioid receptor antagonist used primarily in the management of alcohol dependence, in Korea.
H. Lundbeck ...
Hanwha Chemical undertakes phase 1 trial for generic Embrel
Hanwha Chemical Co. said it has succeeded in conducting Phase 1 local trials for its generic Embrel with positive results.
The company has a plan to conduct the next clinical trials in cooperation with its affiliat...
KFDA approves pazopanib for kidney cancer
The Korea Food and Drug Administration said on August 11 it has approved Pazopanib tablets (Votrient, GlaxoSmithKline) for the treatment of patients with advanced renal cell carcinoma.
Pazotinib is a potent and sel...
Korean Drug sets up joint venture
Korean Drug and BRC have joined forces with Australia based Medinc Co. to set up a joint venture company called “Reach 100 Plus N,” it was learned on August 17.
The newly established company is aiming to market ant...
Major pharmaceutical firms hit by sluggish sales in July
The local market volume for prescription drugs n July this year marked 781.4 billion won, up 0.3 percent from the same month of last year, according to market analysts. The figure was the lowest since October 2008.
...
Pharmaceutical firms want OTCs in supermarket
There is an increasing trend that pharmaceutical companies have launched its task force to tap the possibility of selling over-the-counter drugs in supermarket.
“We are always ready for supermarkets’ marketing of O...
Why do people favor natural vitamin?
Controversy over natural vs. synthetic vitamin is still growing and customers think natural vitamins are more beneficial than synthetic ones due to heated marketing campaign by Yakurt.
In fact, manufacturers of nat...
Competition stiff for cephalosporin market
Many major pharmaceutical manufacturers are rushing to produce cephalosporin antibiotics with hope of acquiring large share of the domestic cephalosporin market valued at 500 billion won, which is forecast to become m...
KFDA approves Vimpat as adjunct antiepileptic drug
The Korea Food and Drug Administration said on August 6 it has approved UCB's Vimpat (lacosamide) for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Vimpat is an orally-available ...
OTC products to rise up to 50 percent
Some drug manufacturers intend to increase their over-the-counter drugs by more than 50 percent, as part of efforts to boost sluggish sales in the domestic market.
Yuyu Pharm said it will increase the price of Beno...
